# Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

> **NCT04135781** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 616 (estimated)

## Conditions studied

- Stomach Cancer

## Interventions

- **DRUG:** nab paclitaxel
- **DRUG:** Tegafur
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04135781
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 616 (ESTIMATED)
- **Last updated:** 2020-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04135781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04135781, "Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04135781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*